Background:- Cardiovascular diseases are a group of disorders of the
heart and blood vessels. Adiponectin is an adipocyte-secreted protein with
insulin-sensitizing and anti-atherogenic properties. Many studies demonstrated
that polymorphisms within the adiponectin gene could be associated in T2DM with
and without CVD. Methods:- A case-control study was conducted to find the
association between SNP rs266729 in T2DM with and without CVD in Al-Najaf
Governorate, Iraq. The study included 203 T2DM patients with CVD randomly
selected based on World Health Organization (WHO) guideline and 133 T2DM
patients without CVD as controls group. DNA was extracted from blood and
genotyped by PCR-RFLP by using (Hha1) enzyme. Multinomial logistic regression
was applied to compare the proportions of genotypes and alleles. The odds ratio
for risk of developing CVD in T2DM was calculated with and without adjustment for
age, sex, and BMI. Results:- The frequency of G allele of rs266729 (C/G)
polymorphism was significantly lower (p=0.0001) in T2DM with CVD (27.3%)
compared to that without CVD (33.08%). The homozygous genotype (GG)
significantly (0R=7.570, CI 95%(1.597-32.530), P= 0.011) increased the risk of
T2DM with CVD seven folds with respect to those of the wild type (CC) after
adjustment age, sex, and BMI, furthermore the heterozygous (CG) genotype
significantly [0R=2.818,CI 95%(1.00-12.596), P= 0.050] raised the risk of T2DM
with CVD by two folds. Homozygous and heterozygous genotypes of rs266729
polymorphism exhibited significant association with decreased adiponectin
levels (P= 0.08). Conclusion:- Adiponectin gene polymorphism rs266729 is
involved in the pathogenesis of T2DM with CVD. In addition this SNP may play a
role in the development of cardiovascular diseases and metabolic syndrome by
affecting HDL and adiponectin levels. - See more at:
No comments:
Post a Comment